Vericel Corp (VCEL) - Financial and Strategic SWOT Analysis Review

March 2021 | 52 pages | ID: V2BBA557AA2EN
GlobalData

Abstracts

Vericel Corp (VCEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vericel Corp (Vericel) develops and markets advanced cell therapies for sports medicine and severe burn care domain. Its major products include MACI (autologous cultured chondrocytes on porcine collagen membrane) for the treatment of cartilage defects; and Epicel cultured epidermal autografts for skin replacement. It also holds an exclusive license for NexoBrid in North America for the treatment of severe thermal burns. The company sells its products through clinical support specialists. Vericel is headquartered in Cambridge, Massachusetts, the US.

Vericel Corp Key Recent Developments

Mar 10,2021: Vericel to Present at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021
Feb 24,2021: Vericel reports fourth quarter and full-year 2020 financial results and provides full-year 2021 financial guidance
Feb 22,2021: Vericel to Present at the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021
Feb 16,2021: Vericel to Participate in the BTIG Virtual MedTech Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021
Jan 25,2021: Vericel announces appointment of Joe Mara as chief financial officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Vericel Corp - Key Facts
Vericel Corp - Key Employees
Vericel Corp - Key Employee Biographies
Vericel Corp - Major Products and Services
Vericel Corp - History
Vericel Corp - Company Statement
Vericel Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Vericel Corp - Business Description
Product Category: Epicel
Overview
Performance
Product Category: MACI
Overview
Performance
Product Category: NexoBrid
Overview
Performance
R&D Overview
Vericel Corp - Corporate Strategy
Vericel Corp - SWOT Analysis
SWOT Analysis - Overview
Vericel Corp - Strengths
Vericel Corp - Weaknesses
Vericel Corp - Opportunities
Vericel Corp - Threats
Vericel Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Vericel Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021
Vericel Corp, Medical Equipment, Deals By Type, 2015 to YTD 2021
Vericel Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 10, 2021: Vericel to Present at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021
Feb 24, 2021: Vericel reports fourth quarter and full-year 2020 financial results and provides full-year 2021 financial guidance
Feb 22, 2021: Vericel to Present at the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021
Feb 16, 2021: Vericel to Participate in the BTIG Virtual MedTech Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021
Jan 25, 2021: Vericel announces appointment of Joe Mara as chief financial officer
Jan 11, 2021: Vericel announces preliminary fourth-quarter and full-year 2020 financial results and provides business updates
Nov 05, 2020: Vericel reports record third quarter revenues and net income
Oct 14, 2020: Vericel announces preliminary third quarter 2020 total net revenues of $32 million
Aug 05, 2020: Vericel reports second quarter 2020 financial results
Jul 09, 2020: Vericel announces preliminary second quarter 2020 financial results and provides business updates

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Vericel Corp, Key Facts
Vericel Corp, Key Employees
Vericel Corp, Key Employee Biographies
Vericel Corp, Major Products and Services
Vericel Corp, History
Vericel Corp, Other Locations
Vericel Corp, Subsidiaries
Vericel Corp, Key Competitors
Vericel Corp, Ratios based on current share price
Vericel Corp, Annual Ratios
Vericel Corp, Annual Ratios (Cont...1)
Vericel Corp, Interim Ratios
Vericel Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021
Vericel Corp, Medical Equipment, Deals By Type, 2015 to YTD 2021
Vericel Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Vericel Corp, Performance Chart (2016 - 2020)
Vericel Corp, Ratio Charts
Vericel Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021
Vericel Corp, Medical Equipment, Deals by Type, 2015 to YTD 2021